NewLink Genetics Corporation (NASDAQ:NLNK) had its price target lifted by investment analysts at Stifel Nicolaus from $25.00 to $29.00 in a research report issued to clients and investors on Friday, The Fly reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 209.83% from the stock’s previous close.

Several other brokerages also recently weighed in on NLNK. Cantor Fitzgerald restated a “buy” rating and set a $26.00 target price on shares of NewLink Genetics Corporation in a research note on Thursday. Robert W. Baird upgraded NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and raised their target price for the company from $8.00 to $22.00 in a research note on Friday, September 8th. Zacks Investment Research downgraded NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Jefferies Group LLC restated a “hold” rating and set a $7.00 target price on shares of NewLink Genetics Corporation in a research note on Friday, July 14th. Finally, Bank of America Corporation started coverage on shares of NewLink Genetics Corporation in a research report on Friday, October 13th. They set a “buy” rating and a $22.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $25.83.

NewLink Genetics Corporation (NASDAQ:NLNK) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.07. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/11/03/stifel-nicolaus-boosts-newlink-genetics-corporation-nlnk-price-target-to-29-00.html.

In related news, major shareholder Stine Seed Farm, Inc. purchased 780,487 shares of NewLink Genetics Corporation stock in a transaction dated Friday, October 6th. The shares were acquired at an average price of $10.25 per share, with a total value of $7,999,991.75. Following the completion of the transaction, the insider now owns 7,857,732 shares of the company’s stock, valued at approximately $80,541,753. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 13.70% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Eqis Capital Management Inc. lifted its position in shares of NewLink Genetics Corporation by 0.6% during the second quarter. Eqis Capital Management Inc. now owns 32,999 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 183 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of NewLink Genetics Corporation by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 556 shares during the last quarter. Advisor Group Inc. lifted its position in shares of NewLink Genetics Corporation by 3.4% during the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 600 shares during the last quarter. American International Group Inc. lifted its position in shares of NewLink Genetics Corporation by 7.1% during the first quarter. American International Group Inc. now owns 13,321 shares of the biotechnology company’s stock worth $321,000 after purchasing an additional 880 shares during the last quarter. Finally, Northwest Wealth Management LLC lifted its position in shares of NewLink Genetics Corporation by 3.1% during the second quarter. Northwest Wealth Management LLC now owns 58,022 shares of the biotechnology company’s stock worth $426,000 after purchasing an additional 1,740 shares during the last quarter. 55.09% of the stock is currently owned by institutional investors and hedge funds.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

The Fly

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.